DEFA14A: Embecta Rebuts ISS on Equity Plan Share Increase

Embecta Corp. issued a supplement to its proxy statement, addressing Institutional Shareholder Services' negative recommendation on a proposal to increase shares for its 2022 equity compensation plan.

Summary

• Embecta Corp. is seeking stockholder approval for Proposal 4, an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan (the "2022 Plan").
• The proposed amendment aims to increase the number of shares available for issuance under the 2022 Plan by 2,430,000 shares.
• The Board of Directors approved the 2022 Plan Amendment on December 2, 2025.
• Institutional Shareholder Services (ISS) issued a report on January 19, 2026, recommending that stockholders vote against Proposal 4.
• ISS's negative recommendation was based on its determination that the stockholder value transfer (SVT) exceeded applicable ISS SVT benchmarks, using a calculation date of September 30, 2025.
• Embecta asserts that its share request was calculated as of November 30, 2025, and believes that correcting ISS's calculation date assumption will bring the plan within ISS guidelines, making the plan cost reasonable.
• As of November 30, 2025, the company had 59,211,232 common shares outstanding and a share reserve of 791,505 under the 2022 Plan.
• The Board reiterates its recommendation for stockholders to vote FOR the approval of Proposal 4 at the Annual Meeting on February 11, 2026.

Sentiment

Score: 5

Explanation: The filing addresses a negative recommendation from a key proxy advisor (ISS) regarding an equity plan amendment. While this introduces a point of contention, the company provides a clear rebuttal and reiterates its board's confidence in the proposal, suggesting a neutral to slightly cautious sentiment as the outcome of the vote remains pending.

Positives

• The Board of Directors unanimously approved the 2022 Plan Amendment on December 2, 2025.
• Management believes the 2022 Plan cost is reasonable and will fall within ISS guidelines if the correct calculation date (November 30, 2025) is used for the stockholder value transfer analysis.
• The company is proactively providing supplemental data to ensure stockholders have accurate, up-to-date information for their voting decision.

Negatives

• Institutional Shareholder Services (ISS) recommended that stockholders vote against the proposal to approve the 2022 Plan Amendment.
• ISS determined that the stockholder value transfer (SVT) exceeded its applicable benchmarks, which could sway institutional investors to vote against the proposal.

Risks

• There is a risk that stockholders, particularly institutional investors influenced by ISS, may vote against Proposal 4, potentially hindering the company's ability to use equity compensation for employee and director incentives.
• Failure to approve the amendment could impact the company's future talent attraction and retention strategies.
• Disagreement with proxy advisory firms like ISS can create uncertainty and require additional communication efforts to secure shareholder support.

Future Outlook

The company is seeking approval for the equity plan amendment to ensure it has sufficient shares available for future equity-based compensation, which is a critical component for attracting, retaining, and incentivizing key employees and directors, aligning their interests with long-term shareholder value creation.

Management Comments

• "The 2022 Plan cost is reasonable."
• "Correcting these assumptions, we believe, will bring our plan within the parameters of ISS guidelines."
• "The Board reiterates its recommendation that you vote FOR the approval of Proposal 4."

Industry Context

Equity compensation plans are a standard and widely adopted mechanism across publicly traded companies to align the interests of management and employees with those of shareholders. Proxy advisory firms like Institutional Shareholder Services (ISS) play a significant role in influencing institutional investor votes on such proposals by providing independent analysis and recommendations based on their proprietary benchmarks and governance policies. Companies often engage with these firms to clarify their positions and data.

Comparison to Industry Standards

• The company's argument that its plan falls within ISS guidelines when calculated correctly implies adherence to a widely recognized benchmark for executive and employee compensation plans.
• ISS's initial assessment that the Stockholder Value Transfer (SVT) exceeded its benchmarks suggests a potential deviation from what ISS considers acceptable industry practice, though the company disputes the basis of this assessment.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on a proposal that could lead to share dilution but is intended to align management and employee incentives with shareholder value. The ISS recommendation against the proposal could influence voting decisions.
• Employees and Directors: The availability of equity-based compensation is a key component of their overall remuneration and incentive structure. Approval of the amendment ensures continued access to these incentives.

Next Steps

• Stockholders will vote on Proposal 4 at the Annual Meeting on February 11, 2026.
• Stockholders who have already voted may change or revoke their prior vote by referring to page 80 of the original Proxy Statement.

Key Dates

Recommendation

The filing primarily addresses a technical disagreement with Institutional Shareholder Services (ISS) regarding the calculation of stockholder value transfer for an equity compensation plan amendment. While ISS recommended against the proposal, the company asserts that its plan is reasonable and within guidelines when correct assumptions are applied. This issue, while important for corporate governance and long-term incentive alignment, does not fundamentally alter the company's operational or financial outlook in a way that warrants a strong buy or sell recommendation based solely on this supplement. Investors should monitor the outcome of the shareholder vote and consider the broader financial health and strategic direction of Embecta Corp.

Keywords

Embecta Corp, Equity Compensation Plan, Stockholder Value Transfer, Proxy Statement, ISS Recommendation, Employee Stock Plan, Corporate Governance, Shareholder Vote, DEFA14A